Pediatric Cancer Studies: US FDA’s Molecular Target Lists Face Panel Vetting

 
• By Sue Sutter
  
Target hit in center by arrows. 3d illustration. Sunrise on background
A drug aimed at a molecular target that is substantially relevant to pediatric cancer might face additional studies under a recent US law.

More from US FDA Performance Tracker

More from Regulatory Trackers